Digital Therapeutics Psoriatic Arthritis Market Size, Share & Growth Analysis, 2026-2034

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Digital Therapeutics Psoriatic Arthritis Market Size and Growth Outlook

Across all regions, the Digital Therapeutics for Psoriatic Arthritis market size reached USD 1.50 billion in 2025, reflecting a robust surge in digital health adoption across the globe. With consistent increase in demand for advanced, non-pharmacological and complementary interventions, the market is set to register a Compound Annual Growth Rate (CAGR) of 18.4% from 2026 to 2034. By the end of 2034, the market is forecasted to attain a value of approximately USD 6.72 billion. This remarkable growth is primarily driven by the rising prevalence of psoriatic arthritis, increasing awareness about digital therapeutics, and the integration of artificial intelligence and machine learning in patient-centric digital health solutions.

Get Free Sample Report

One of the most significant growth factors for the Digital Therapeutics for Psoriatic Arthritis market is the global surge in psoriatic arthritis cases, which has heightened the need for innovative disease management solutions. Traditional treatments often focus on pharmacological interventions, but limitations associated with long-term drug use, such as side effects and diminishing efficacy, have propelled the adoption of digital therapeutics. These solutions leverage software-based interventions to provide personalized care, real-time monitoring, and symptom tracking, thereby enhancing patient outcomes and engagement. The growing emphasis on patient-centric care and the shift toward value-based healthcare models further underscore the importance of digital therapeutics in managing chronic conditions like psoriatic arthritis. The broader context of digital therapeutics for inflammatory skin and joint conditions highlights how software-driven care is reshaping the dermatology and rheumatology landscape in 2025 and beyond.

Another key driver is the rapid advancement in digital health technologies, including the proliferation of smartphones, wearable devices, and telemedicine platforms. These technologies allow seamless integration of digital therapeutics into daily patient routines, enabling continuous disease monitoring, remote consultations, and tailored intervention strategies. Furthermore, increasing investments by both public and private sectors in digital health infrastructure, coupled with favorable regulatory frameworks such as the FDA's expanded digital health pathways, are accelerating the development and deployment of digital therapeutics for psoriatic arthritis. Ongoing collaboration between technology providers, healthcare institutions, and pharmaceutical companies is fostering innovation and expanding the market's reach to previously underserved populations. The parallel expansion seen in digital therapeutics for atopic dermatitis demonstrates how evidence-based app-delivered interventions are gaining traction across multiple chronic immune-mediated conditions.

The evolving reimbursement landscape is also fueling the growth of the Digital Therapeutics for Psoriatic Arthritis market. As healthcare payers and policymakers recognize the clinical and economic benefits of digital interventions, there is a notable increase in reimbursement policies for prescription digital therapeutics (PDTs). This shift is encouraging healthcare providers to integrate these solutions into standard care protocols, driving higher adoption rates. Additionally, the lasting impact of the COVID-19 pandemic has cemented the acceptance of remote healthcare solutions, further validating the efficacy and convenience of digital therapeutics in chronic disease management. By 2025, both patients and providers are routinely relying on digital platforms for ongoing disease monitoring, education, and management, setting a strong foundation for the 2026-2034 forecast period.

From a regional perspective, North America continues to lead the market, supported by a technologically advanced healthcare ecosystem, high prevalence of psoriatic arthritis, and strong presence of key industry players. Europe follows closely, benefiting from robust government initiatives and widespread adoption of digital health solutions. Meanwhile, the Asia Pacific region is witnessing the fastest growth, driven by increasing healthcare digitization, rising disease awareness, and expanding healthcare access in emerging economies. Despite variations in regulatory environments and healthcare infrastructure, the global outlook for digital therapeutics in psoriatic arthritis remains overwhelmingly positive, with ample opportunities for expansion and innovation through 2034.

Digital Therapeutics Psoriatic Arthritis Market by Product Type

The Product Type segment of the Digital Therapeutics for Psoriatic Arthritis market is categorized into Software Applications, Devices, and Platforms. Among these, software applications account for the largest market share in 2025 at approximately 52.5%, primarily due to their ease of integration with existing healthcare systems and the rapid adoption of mobile health apps. These applications offer tailored interventions, real-time symptom tracking, and clinical decision support tools for both patients and clinicians. The increasing sophistication of these apps, powered by artificial intelligence and machine learning algorithms, enables personalized disease management plans that significantly improve patient outcomes and adherence rates. Notable examples include AI-driven musculoskeletal apps from companies such as Kaia Health Software GmbH and behavioral digital therapeutics from Happify Health, which are expanding their clinical evidence bases in 2025.

Get Free Sample Report

Devices, including wearable sensors and remote monitoring tools, account for roughly 27.5% of the 2025 market and are gaining traction as they provide continuous data on patient activity, joint load, and treatment effectiveness. These devices facilitate proactive disease management by alerting patients and healthcare providers to potential flare-ups or deviations from treatment plans. The integration of devices with software applications creates a comprehensive digital ecosystem, allowing for seamless data exchange and enhanced patient engagement. Companies such as Biofourmis and Propeller Health (a ResMed company) are at the forefront of combining sensor-based hardware with intelligent analytics platforms, improving the accuracy and actionability of real-world data for psoriatic arthritis patients.

Platforms, which serve as centralized hubs for managing and analyzing patient data, represent approximately 20.0% of the 2025 market and are witnessing increased adoption. These platforms aggregate information from various sources, including software applications and devices, to provide a holistic view of the patient's health status. They enable healthcare providers to monitor large patient populations efficiently, identify trends, and make data-driven decisions. Platforms also facilitate communication between patients, providers, and caregivers, fostering a collaborative approach to disease management. The growing emphasis on interoperability with electronic health records (EHRs) and data security is driving innovation in platform development, ensuring compliance with regulatory standards such as HIPAA and GDPR while safeguarding patient privacy.

The convergence of software applications, devices, and platforms is creating a synergistic effect, enhancing the overall efficacy of digital therapeutics for psoriatic arthritis. Companies are increasingly focusing on developing integrated solutions that combine the strengths of each product type, offering comprehensive care pathways that address the unique needs of individual patients. This trend is expected to accelerate through 2034, with ongoing investments in research and development leading to next-generation digital therapeutics that leverage advanced analytics, generative AI, and real-world evidence to optimize disease management. The cross-pollination of innovation seen in adjacent markets, such as digital therapeutics for fibromyalgia and chronic pain, is providing valuable technology transfer opportunities that benefit psoriatic arthritis platforms as well.

Digital Therapeutics Psoriatic Arthritis Market Report Scope

Digital Therapeutics Psoriatic Arthritis Market by Application

Within the Application segment, Disease Management dominates the market, accounting for the largest share in 2025. Digital therapeutics solutions in this category are designed to provide continuous support for patients, helping them adhere to treatment regimens, monitor symptoms, and manage comorbidities such as cardiovascular disease and metabolic syndrome that frequently co-occur with psoriatic arthritis. These applications utilize evidence-based protocols to deliver personalized interventions, track disease progression, and offer actionable insights to both patients and healthcare providers. The integration of remote monitoring and telehealth functionalities further enhances the effectiveness of disease management solutions, enabling timely adjustments to treatment plans and reducing the risk of complications.

Symptom Tracking is another critical application area, offering patients the ability to record and monitor their symptoms in real time. This functionality empowers patients to take an active role in their care, facilitating early detection of flare-ups and enabling prompt intervention. Symptom tracking tools often incorporate validated patient-reported outcome measures (PROMs), visual analog scales, and automated alerts, providing valuable data for clinical decision-making. The widespread adoption of smartphones and wearable devices has made symptom tracking more accessible and user-friendly in 2025, contributing to higher engagement and improved disease outcomes across both urban and rural patient populations.

Patient Education is an emerging and rapidly growing application segment that focuses on empowering patients with the knowledge and skills needed to manage their condition effectively. Digital therapeutics platforms offer a wide range of educational resources, including interactive modules, videos, and personalized AI coaching. These resources are designed to improve health literacy, promote self-management, and foster sustainable behavioral change. By enhancing patient understanding of psoriatic arthritis and its treatment options, digital education tools play a vital role in improving adherence and reducing the burden on healthcare systems. In 2025, this segment is being further energized by advances in large language model-powered chatbots that can answer patient questions around the clock.

Other applications, such as medication adherence support, lifestyle modification guidance, and psychosocial support, are also gaining prominence in the digital therapeutics landscape. These solutions address the multifaceted needs of psoriatic arthritis patients, providing holistic care that extends beyond traditional medical interventions. The growing recognition of mental health comorbidities in psoriatic arthritis, including depression and anxiety, is driving the development of multifunctional digital therapeutics platforms that integrate behavioral health tools. Companies such as Omada Health and Happify Health are expanding their chronic condition platforms to cover the psychosocial dimensions of autoimmune disease management, a trend expected to intensify through 2034.

Digital Therapeutics Psoriatic Arthritis Market by End-User

The End-User segment comprises Hospitals, Clinics, Homecare, and Others. Hospitals represent the largest end-user category in 2025, leveraging digital therapeutics to enhance clinical workflows, optimize resource utilization, and improve patient outcomes. The integration of digital therapeutics into hospital settings enables multidisciplinary care teams to monitor patients remotely, adjust treatment plans in real time, and reduce hospital readmissions. Major academic medical centers and health systems in the United States and Europe are piloting prescription digital therapeutic programs as adjuncts to biologic therapy, recognizing their potential to drive cost savings and improve quality-of-care metrics.

Clinics, particularly rheumatology and dermatology clinics, are increasingly adopting digital therapeutics to streamline patient management and enhance care coordination. These settings benefit from the ability to monitor patients between visits, identify early signs of disease progression, and deliver targeted interventions. The use of digital therapeutics in clinics also facilitates data sharing and collaboration among healthcare providers, leading to more informed decision-making and better patient outcomes. As specialty clinics continue to embrace digital health technologies through 2034, their role in the digital therapeutics ecosystem is expected to expand meaningfully, supported by growing payer reimbursement for remote patient monitoring.

Homecare is emerging as the fastest-growing end-user segment, driven by the strong patient preference for remote care and self-management among individuals with chronic conditions. Digital therapeutics solutions designed for home use empower patients to take control of their health, monitor symptoms, and communicate with healthcare providers from the comfort of their homes. This approach not only improves patient satisfaction but also reduces the burden on healthcare facilities and lowers overall healthcare costs. The increasing availability of user-friendly apps from companies such as Hinge Health, Sword Health, and Mymee Inc. is making home-based digital therapeutics more accessible to a wider psoriatic arthritis patient population in 2025.

Other end-users, including research institutions, pharmaceutical companies, and payers, are also recognizing the strategic value of digital therapeutics in psoriatic arthritis management. These stakeholders are leveraging digital solutions to conduct decentralized clinical trials, develop companion digital therapeutics for biologic drugs, and assess real-world outcomes for coverage decisions. The involvement of a diverse range of end-users is fostering innovation and driving the adoption of digital therapeutics across the healthcare ecosystem. As the market continues to evolve through 2034, collaboration among end-users will be essential to maximize the clinical and economic impact of digital therapeutics on psoriatic arthritis patient care.

Digital Therapeutics Psoriatic Arthritis Market by Distribution Channel

The Distribution Channel segment is bifurcated into Online and Offline channels. Online distribution channels have emerged as the dominant mode of delivery, accounting for the majority of market share in 2025. The proliferation of e-commerce platforms, mobile app stores such as the Apple App Store and Google Play, and dedicated telehealth portals has made it easier for patients and healthcare providers to access and deploy digital therapeutics solutions. Online channels offer several advantages, including convenience, global reach, and the ability to deliver real-time updates, personalized content, and remote technical support. The lasting structural shift toward virtual care that followed the COVID-19 pandemic has permanently elevated online channels as the primary distribution mechanism for digital therapeutics.

Offline distribution channels, such as hospital pharmacies, specialty clinics, and retail health stores, continue to play a vital role, particularly in regions with limited digital infrastructure and among older patient populations. These channels provide opportunities for in-person education, product demonstrations, device setup, and technical support, which are essential for certain patient segments. Offline channels also facilitate the integration of digital therapeutics with traditional healthcare services, enabling a hybrid approach that combines the benefits of digital and in-person care. Despite the rapid growth of online channels, offline distribution remains important for ensuring equitable access to digital therapeutics across diverse demographic and geographic populations.

The integration of online and offline channels is creating a seamless omnichannel experience for patients and healthcare providers. Companies are increasingly adopting hybrid distribution strategies to maximize market reach and cater to the unique needs of different regions and patient segments through 2034. This approach enables patients to access digital therapeutics through their preferred channels, enhancing convenience and long-term engagement. The ongoing evolution of distribution models, including direct-to-employer and direct-to-payer partnerships, is expected to drive further growth in the digital therapeutics market as companies seek to optimize their go-to-market strategies and expand their global footprint beyond traditional healthcare channels.

As the market matures, the role of distribution channels in shaping patient access and adoption of digital therapeutics will become increasingly important. Companies that effectively leverage both online and offline channels, while ensuring compliance with regulatory requirements and maintaining high standards of data security and privacy, will be well-positioned to capitalize on the growing demand for digital therapeutics in psoriatic arthritis management throughout the 2026-2034 forecast period.

Digital Therapeutics Psoriatic Arthritis Market Opportunities and Threats

The Digital Therapeutics for Psoriatic Arthritis market presents a wealth of opportunities for stakeholders across the healthcare ecosystem as of 2025. One of the most promising opportunities lies in the integration of generative AI, large language models, and advanced real-world data analytics into digital therapeutics solutions. These technologies enable the development of highly personalized interventions, predictive flare-up analytics, and continuous monitoring capabilities that can significantly improve patient outcomes and reduce total cost of care. Additionally, the expansion of telemedicine and remote care services is opening new avenues for delivering digital therapeutics to underserved and geographically remote populations, thereby expanding the market's reach and social impact.

Another key opportunity is the growing acceptance of digital therapeutics among healthcare providers, payers, and patients. As clinical evidence continues to accumulate from randomized controlled trials and real-world studies, there is increasing support for the integration of digital therapeutics into standard care protocols and insurance reimbursement frameworks. This shift is creating a favorable environment for market growth, encouraging investment in research and development, and fostering collaboration among technology providers, healthcare institutions, and pharmaceutical companies. The establishment of clear regulatory pathways for prescription digital therapeutics in major markets, including the United States, Germany (DiGA), and the United Kingdom, is creating a more predictable and commercially viable landscape for market participants through 2034.

Despite the numerous opportunities, the market faces several restraining factors that could hinder its growth. One of the primary challenges is the heterogeneity of regulatory frameworks and reimbursement policies for digital therapeutics across different geographies. This variability creates market entry complexity and can impede scale for companies seeking international expansion. Concerns about data security, patient privacy, and interoperability with legacy EHR systems remain significant technical and compliance barriers. Additionally, patient digital literacy and engagement fatigue, particularly among older populations managing multiple chronic conditions, pose adoption challenges. Demonstrating durable real-world clinical efficacy that satisfies payer requirements for reimbursement will remain a critical and ongoing challenge for all market participants through 2034.

Digital Therapeutics Psoriatic Arthritis Market Size by Region

The North American region leads the global Digital Therapeutics for Psoriatic Arthritis market, with a market size of approximately USD 567 million in 2025, representing about 37.8% of the global total. This dominance is attributed to the region's advanced healthcare infrastructure, high prevalence of psoriatic arthritis, and strong presence of key industry players including Omada Health, Hinge Health, Click Therapeutics, and Teladoc Health. The United States accounts for the largest share within North America, driven by robust investment in digital health technologies, expanding reimbursement for prescription digital therapeutics and remote patient monitoring, and widespread adoption of telehealth following COVID-19. The region's continued focus on innovation, value-based care contracts, and patient-centric outcomes is expected to sustain its leadership position throughout the 2026-2034 forecast period.

Get Free Sample Report

Europe is the second-largest market, with a market size of around USD 398 million in 2025, representing approximately 26.5% of the global market. The region benefits from proactive government initiatives to promote digital health, including Germany's Digital Health Applications (DiGA) fast-track reimbursement pathway, which has created a replicable model now being adopted across the European Union. Countries such as Germany, the United Kingdom, and France are at the forefront of this trend, supported by strong regulatory frameworks and sustained public investment in healthcare digitization. The European market is projected to grow at a CAGR of approximately 17.2% from 2026 to 2034, driven by ongoing advancements in AI-powered therapeutics and expansion of telehealth reimbursement across member states.

The Asia Pacific region is witnessing the fastest growth, with a market size of USD 332 million in 2025 and an anticipated CAGR of 21.5% through 2034. This rapid expansion is fueled by increasing healthcare digitization, rising awareness of chronic autoimmune diseases, and expanding access to healthcare services in emerging economies such as China, India, and Japan. The region's large and diverse patient population, coupled with government-led digital health initiatives and rising smartphone penetration, presents significant growth opportunities for market participants. As digital therapeutics become more accessible and culturally adapted for local populations, the Asia Pacific market is poised to claim a larger share of the global market by 2034, potentially rivaling Europe in absolute size. Latin America accounts for approximately 7.8% of the 2025 market and Middle East and Africa for about 5.8%, with both regions showing accelerating digitization trends expected to sustain above-average CAGRs through the forecast period.

Digital Therapeutics Psoriatic Arthritis Market Competitive Landscape

The competitive landscape of the Digital Therapeutics for Psoriatic Arthritis market in 2025 is characterized by a dynamic mix of pure-play digital health companies, digital health divisions within large pharmaceutical organizations, and strategic collaborations among technology providers, pharma companies, and healthcare institutions. The market is highly competitive, with companies differentiating on the basis of clinical evidence, AI sophistication, user experience, payer integration, and regulatory clearance status. Leading players are investing heavily in real-world evidence generation and randomized controlled trial data to satisfy payer reimbursement requirements, while also focusing on regulatory compliance, cybersecurity, and EHR interoperability to build trust among institutional customers.

Strategic partnerships and collaborations are playing a crucial role in driving market growth and expanding the reach of digital therapeutics solutions. Companies are joining forces with healthcare providers, insurers, and patient advocacy communities to develop evidence-based interventions, conduct decentralized clinical trials, and facilitate the integration of digital therapeutics into standard rheumatology care pathways. Mergers and acquisitions continue to consolidate the market, as larger health platforms seek to acquire specialized point solutions and integrate them into broader chronic condition management ecosystems. Pharmaceutical companies including AbbVie, Novartis, UCB, and Eli Lilly are increasingly partnering with or acquiring digital health developers to create companion digital therapeutics for their established biologic and small-molecule therapies for psoriatic arthritis.

The market is also witnessing increased activity from digital musculoskeletal (MSK) health companies. Hinge Health and Sword Health have expanded their condition coverage from general musculoskeletal pain into specific inflammatory arthritis programs, while Mymee Inc. has built a data-driven trigger-identification platform specifically for autoimmune conditions including psoriatic arthritis. Kaia Health Software GmbH continues to expand its AI-powered musculoskeletal therapy platform with growing clinical evidence across European and North American markets. Biofourmis is leveraging its predictive analytics engine and wearable biosensor ecosystem to serve both patients and pharmaceutical clients conducting remote clinical trials in rheumatology.

Click Therapeutics stands out as a leader in prescription digital therapeutics, developing FDA-regulated software-based interventions with disease-specific targeting and robust clinical trial programs. Teladoc Health's chronic condition management platform, combined with its telehealth infrastructure, gives it a unique position to integrate digital therapeutics delivery with virtual physician consultations at scale. Happify Health focuses on the mental and behavioral health dimensions of chronic disease management, offering validated digital interventions that address depression, anxiety, and treatment adherence challenges common among psoriatic arthritis patients. MyHealthTeams operates a peer support social network specifically for psoriatic arthritis patients, creating a data-rich community platform that complements clinical digital therapeutics with patient-generated insights. Together, these companies and their peers are shaping a rapidly maturing, evidence-driven market that is expected to deliver substantial clinical and economic value through 2034.

Top Companies in the Digital Therapeutics Psoriatic Arthritis Market

• Kaia Health Software GmbH
• Click Therapeutics Inc.
• Happify Health
• Mymee Inc.
• Propeller Health (ResMed)
• Sword Health
• Hinge Health
• Nuvation Bio Inc.
• Omada Health
• Teladoc Health Inc.
• Biofourmis Inc.
• Liminal BioSciences
• Novartis AG
• AbbVie Inc.
• UCB S.A.
• Pfizer Inc.
• Eli Lilly and Company
• Leo Pharma A/S
• MyHealthTeams
• Galapagos NV